Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.54 |
| ▸ | HTT | P42858 | 3/20 | 0.52 |
| ▸ | ATM | Q13315 | 1/20 | 0.51 |
| ▸ | MAPT | P10636 | 2/20 | 0.50 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.49 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.49 |
| ▸ | HPGD | P15428 | 3/20 | 0.48 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.48 |
| ▸ | RAB9A | P51151 | 3/20 | 0.46 |
| ▸ | IKBKB | O14920 | 1/20 | 0.45 |
| ▸ | PPARD | Q03181 | 1/20 | 0.45 |
| ▸ | PPARA | Q07869 | 1/20 | 0.45 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.44 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.44 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.44 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.44 |
| ▸ | NPC1 | O15118 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31105839 | 1.00 | KDM4E (0.57) | KDM4EALDH1A1SMN1; SMN2HTTATM | |
| SCHEMBL30923332 | 0.83 | ALDH1A1 (0.54) | KDM4EALDH1A1SMN1; SMN2HTTMAPT | |
| SCHEMBL2203793 | 0.83 | ALDH1A1 (0.54) | KDM4EALDH1A1SMN1; SMN2HTTMAPT | |
| SCHEMBL26617865 | 0.83 | RXFP1 (0.70) | KDM4EALDH1A1SMN1; SMN2MAPTRXFP1 | |
| SCHEMBL68891 | 0.82 | KDM4E (0.51) | KDM4EALDH1A1SMN1; SMN2HTTMAPT | |
| SCHEMBL30201832 | 0.82 | SMN1; SMN2 (0.60) | KDM4EALDH1A1SMN1; SMN2HTTMAPT | |
| SCHEMBL16234345 | 0.82 | KDM4E (0.51) | KDM4EALDH1A1SMN1; SMN2HTTMAPT | |
| SCHEMBL3144090 | 0.81 | KDM4E (0.55) | KDM4EALDH1A1SMN1; SMN2HTTATM | |
| SCHEMBL15923319 | 0.81 | MAPT (0.64) | KDM4EALDH1A1SMN1; SMN2HTTATM | |
| SCHEMBL6097776 | 0.81 | ABCG2 (0.55) | KDM4EALDH1A1SMN1; SMN2HTTATM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119285543-B | Sulfonylation method of halogenated quinoline and aryl sulfonyl hydrazine | 南京工业大学 | 2026-05-15 | — | — | CN | claimed |
| US-20250188040-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING WRN HELICASE INHIBITORS | VIVIDION THERAPEUTICS INC | 2025-06-12 | — | — | US | disclosed |
| EP-4551555-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING WRN HELICASE INHIBITORS | Vividion Therapeutics, Inc. (US) | 2025-05-14 | — | — | EP | disclosed |
| CN-119874606-A | Fused piperidinyl bicyclic and related compounds as modulators of C5a receptors | 因弗拉克斯有限责任公司 | 2025-04-25 | — | — | CN | disclosed |
| CN-119677716-A | Pharmaceutical compositions comprising WRN helicase inhibitors | 维维迪恩医疗公司 | 2025-03-21 | — | — | CN | disclosed |
| CN-113784955-B | Fused piperidinyl bicyclic and related compounds as modulators of C5a receptors | 因弗拉克斯有限责任公司 | 2025-02-14 | — | — | CN | disclosed |
| US-12187685-B2 | Pharmaceutical compositions comprising WRN helicase inhibitors | VIVIDION THERAPEUTICS, INC. | 2025-01-07 | — | — | US | disclosed |
| US-20240300898-A1 | FUSED PIPERIDINYL BICYCLIC AND RELATED COMPOUNDS AS MODULATORS OF C5A RECEPTOR | INFLARX GMBH (DE) | 2024-09-12 | — | — | US | disclosed |
| US-11999698-B2 | Fused piperidinyl bicyclic and related compounds as modulators of C5a receptor | INFLARX GMBH (DE) | 2024-06-04 | — | — | US | disclosed |
| US-20240140915-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING WRN HELICASE INHIBITORS | VIVIDION THERAPEUTICS, INC. | 2024-05-02 | — | — | US | disclosed |
| US-10881666-B2 | Combination pharmaceutical agents as RSV inhibitors | ENANTA PHARMACEUTICALS, INC. (US) | 2021-01-05 | — | — | US | disclosed |
| US-10865215-B2 | Benzodiazepine derivatives as RSV inhibitors | ENANTA PHARMACEUTICALS, INC. (US) | 2020-12-15 | — | — | US | disclosed |
| US-20200290969-A1 | FUSED PIPERIDINYL BICYCLIC AND RELATED COMPOUNDS AS MODULATORS OF C5A RECEPTOR | INFLARX GMBH (DE) | 2020-09-17 | — | — | US | disclosed |
| US-20200290969-A1 | FUSED PIPERIDINYL BICYCLIC AND RELATED COMPOUNDS AS MODULATORS OF C5A RECEPTOR | INFLARX GMBH (DE) | 2020-09-17 | — | — | US | disclosed |
| WO-2020182384-A1 | FUSED PIPERIDINYL BICYCLIC AND RELATED COMPOUNDS AS MODULATORS OF C5A RECEPTOR | INFLARX GMBH (DE) | 2020-09-17 | — | — | WO | disclosed |
| US-20200223867-A1 | BENZODIAZEPINE DERIVATIVES AS RSV INHIBITORS | ENANTA PHARM INC (US) | 2020-07-16 | — | — | US | disclosed |
| US-10570153-B2 | Benzodiazepine derivatives as RSV inhibitors | ENANTA PHARMACEUTICALS, INC. (US) | 2020-02-25 | — | — | US | disclosed |
| US-20190192535-A1 | COMBINATION PHARMACEUTICAL AGENTS AS RSV INHIBITORS | ENANTA PHARMACEUTICALS, INC. | 2019-06-27 | — | — | US | disclosed |
| WO-2019067864-A1 | COMBINATION PHARMACEUTICAL AGENTS AS RSV INHIBITORS | ENANTA PHARMACEUTICALS, INC. (US) | 2019-04-04 | — | — | WO | disclosed |
| US-9957281-B2 | Benzodiazepine derivatives as RSV inhibitors | ENANTA PHARMACEUTICALS, INC. (US) | 2018-05-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10865215-B2 | Benzodiazepine derivatives as RSV inhibitors | GABRA5, GABRA1, GABBR2 | KDM4E 1198/4885ALDH1A1 621/4885SMN1; SMN2 627/4885 |
| US-10881666-B2 | Combination pharmaceutical agents as RSV inhibitors | SERPINB1, FURIN, HIF1AN | KDM4E 3876/4885ALDH1A1 3562/4885SMN1; SMN2 709/4885 |
| US-11999698-B2 | Fused piperidinyl bicyclic and related compounds as modulators of C5a receptor | C5AR1, C5AR2, C3AR1 | KDM4E 3743/4885ALDH1A1 4107/4885SMN1; SMN2 3742/4885 |
| US-10570153-B2 | Benzodiazepine derivatives as RSV inhibitors | GABRA5, GABRA1, GABBR2 | KDM4E 1198/4885ALDH1A1 621/4885SMN1; SMN2 627/4885 |
| US-20200290969-A1 | FUSED PIPERIDINYL BICYCLIC AND RELATED COMPOUNDS AS MODULATORS OF C5A RECEPTOR | C5AR1, C5AR2, C3AR1 | KDM4E 3743/4885ALDH1A1 4107/4885SMN1; SMN2 3742/4885 |
| US-20240140915-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING WRN HELICASE INHIBITORS | RECQL, BLM, WRN | KDM4E 3220/4885ALDH1A1 2371/4885SMN1; SMN2 1014/4885 |
| US-12187685-B2 | Pharmaceutical compositions comprising WRN helicase inhibitors | RECQL, BLM, WRN | KDM4E 3220/4885ALDH1A1 2371/4885SMN1; SMN2 1014/4885 |
| US-20200223867-A1 | BENZODIAZEPINE DERIVATIVES AS RSV INHIBITORS | GABRA5, GABRA1, GABBR2 | KDM4E 1198/4885ALDH1A1 621/4885SMN1; SMN2 627/4885 |
| US-20240300898-A1 | FUSED PIPERIDINYL BICYCLIC AND RELATED COMPOUNDS AS MODULATORS OF C5A RECEPTOR | C5AR1, C5AR2, C3AR1 | KDM4E 3743/4885ALDH1A1 4107/4885SMN1; SMN2 3742/4885 |
| US-20250188040-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING WRN HELICASE INHIBITORS | RECQL, BLM, WRN | KDM4E 3220/4885ALDH1A1 2371/4885SMN1; SMN2 1014/4885 |
| US-20190192535-A1 | COMBINATION PHARMACEUTICAL AGENTS AS RSV INHIBITORS | SERPINB1, FURIN, HIF1AN | KDM4E 3876/4885ALDH1A1 3562/4885SMN1; SMN2 709/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.